By Nick Paul Taylor
Caribou Biosciences is nursing a hangover. Weeks after celebrating a 100% overall response rate, the CRISPR biotech has revealed 50% of patients relapsed within six months of receiving its allogeneic CAR-T cell therapy, sending its stock suddenly into a 13% dive that largely erased earlier gains.
read more
By Eric Sagonowsky
In the span of a single year, Biogen went from winning accelerated approval for its Alzheimer’s drug, Aduhelm, to all but abandoning the controversial medicine. Now, Congress is weighing changes to the FDA program that triggered the entire episode.
read more
By Andrea Park
“Recently we’ve received a few complaints from our customers that the foam is disintegrating,” a Philips engineer wrote in 2018. “The material sheds and is pulled into the ventilator air path. As you can imagine, this is not a good situation for our users.”
read more
By Nick Paul Taylor
GSK’s respiratory syncytial virus (RSV) vaccine has hit the mark in a phase 3 trial in older adults, teeing the company up to file for approval by the end of the year. But the data-devoid statement leaves the big question of how the vaccine will fare in a competitive, blockbuster market unanswered.
read more
By Paige Minemyer
Adhering to evidence-based guidelines in cancer care can lead to notable cost reductions, according to two new studies from CVS Health.
read more
By Teresa Carey
This week on "The Top Line," we discuss our special report on the rising stars in the digital health sector. We also talk about surprising data from this weekend’s ASCO meeting and the week's other big headlines. Plus, we're back in person at the biggest conferences!
read more
By Andrea Park
Beta Bionics’ offering is a pocket-sized device that’s equipped with algorithms to automatically dose insulin. Unlike other insulin pumps, however, the iLet system doesn’t require users to set insulin basal rates, glucose correction factors or other insulin regimen parameters, nor do they have to calculate carbohydrates at every meal to determine bolus insulin doses.
read more
By Robert King
The White House is taking money from domestic testing manufacturing and equipment storage to ensure it can buy vaccines in the fall as a congressional aid package remains in limbo.
read more
By Max Bayer
Following the company’s first drug approval in 2021, ADC Therapeutics is looking for FDA nods, and appears to have landed on phase 2 data for a Hodgkin lymphoma drug that could do just that.
read more
By Eric Sagonowsky
After stumbling in the all-important U.S. market, struggling Amarin has scored a needed win overseas. In the U.K., the National Institute for Health and Care Excellence has endorsed Vazkepa for about 425,000 patients with elevated levels of triglycerides, a type of blood fat.
read more
By Conor Hale
Corvia Medical snagged $54 million, which it hopes will help it complete clinical testing for its minimally invasive implant to keep symptoms from worsening in patients with heart failure despite a large clinical trial failing to show benefits in a broad patient population.
read more
By Conor Hale
The advent of artificial intelligence in medicine has long been touted as a way to deliver care where specialists can be hard to come by.
read more
